ClinicalTrials.gg
CompletedNCT06136832PVIUpdated Jul 8, 2025

Pneumonia Vaccine Education Intervention Study

An interventional study of Pneumococcal Vaccine Education in Pneumonia, Pneumococcal and Vaccine, sponsored by Geisinger Clinic. Completed at 1 site in United States. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2025-07-08.

Sponsored by Geisinger Clinic · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
141
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 12 studies in Pneumonia, Pneumococcal with a site in United States — none open to participants now, none under way, none of them phase 3. Pneumonia, Pneumococcal · United States.

Enrollment
9th of 11
141 · median 431
Started
2024
the only one that year
No phase
3 of 12
none open now
Registered
12th of 12
by date
Lead sponsor
1 of 12
Geisinger Clinic

Among the 12 studies in Pneumonia, Pneumococcal with a site in United States, this one is the 9th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2024, is one of 3 with no phase, and was the 12th registered.

Pneumonia, Pneumococcal

44 studies on the registry are indexed under Pneumonia, Pneumococcal; 2 are open to participants now.

Browse Pneumonia, Pneumococcal studies →

Open to participants now

None of the 12 studies in Pneumonia, Pneumococcal with a site in United States is open now. The open studies under Pneumonia, Pneumococcal, anywhere →

Who these studies take

Of the 1 Pneumonia, Pneumococcal study recruiting now, 1 sets no upper age limit and none stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Pneumonia, Pneumococcal with a site in United States as a file.
02

Study summary

The goal of this interventional clinical trial is to investigate the impact of medicine and pharmacy-led education on patient acceptance rates of Prevnar 20 pneumonia vaccination in patients eligible to receive the vaccine. The education intervention and subsequent option to get the vaccine will be done while the patient is admitted to inpatient care, prior to discharge. The main questions the study aims to answer are:

  • Will supplemental education about the Prevnar 20 Pneumococcal vaccine influence patient acceptance rates when given a decision to receive it?
  • Is there any other statistically relevant qualitative reasoning behind the patient's final decision for accepting or refusing the vaccine?
Read the detailed description

BACKGROUND

Pneumococcal disease, a significant cause of morbidity and mortality in at-risk adult populations, remains substantially under-vaccinated despite the availability of an effective vaccine and clear guidelines for its administration. Addressing this issue is of paramount importance to public health, and this study focuses on enhancing the rates of Pneumococcal vaccine acceptance through pharmacy-led patient education during hospital admissions.

Previous research suggests that hospital environments, outside of primary care, present an opportunity for vaccination, especially in the acute care setting and many previous studies have attempted different types of interventions for the influenza vaccines and previous pneumococcal vaccines. In these studies, improvements in vaccination rates were seen from interventions including dedicated clinics, standing orders, strong provider recommendations, reminder systems, and pharmacists screening and educating patients in collaboration with nursing. There is also evidence that collaborative efforts with pharmacy and nursing have shown significant increases in vaccination rates. The role of the pharmacy student was also evaluated in previous studies which showed a 20% increase in vaccination rates with little increase in resources used. While multiple strategies have been employed over the years to improve vaccine uptake, there's a significant hurdle to overcome in patient refusal. Pharmacist led interventions were shown to increase the rate of vaccination in the inpatient setting, however refusal rates remain high, showing the need for a more tailored approach. A review of the relationship between demographic factors and adult immunization rates showed that higher education and income levels correlated with increased vaccination rates and more informed attitudes, however, a deeper dive into the reason behind refusal in warranted to help overcome the hurdle. A notable factor that remains unknown is having a better understanding the patient's viewpoint towards vaccines. Keeping this in mind, this study will use a physician-pharmacy collaborative intervention as method to enhance vaccine acceptance rates, but more importantly, will collect information on the impact of the intervention through surveying the patient's viewpoint behind their decision.

This study will target adult patients admitted to the hospital who fall under the recommended criteria for the Pneumococcal vaccine, especially those aged 65 years or older and at-risk categories. The primary endpoint will be the rate of Pneumococcal vaccine acceptance among eligible patients' post-pharmacy intervention compared to standard care without the intervention.

It is anticipated that there will be an increase in the rates of Pneumococcal vaccine acceptance post-pharmacy intervention. The rationale behind this hypothesis is built upon the foundational understanding that personal interaction and education by a pharmacist can provide a level of clarity, confidence, and trust in patients. Potential pitfalls could include resistance from patients due to prior beliefs or misconceptions about vaccines, administrative challenges in implementing pharmacy-led interventions, or logistical issues in vaccine supply. The secondary endpoint of the study will be to uncover some of the reasons behind refusal of the vaccine by surveying all patients regarding the reason for their decision.

Improving pneumococcal vaccination rates has direct benefits both for individual participants and society. The individual gets protection against potentially severe infections, and at a societal level, this translates to reduced healthcare burdens, less strain on resources, and better public health outcomes. Increasing vaccine acceptance contributes to herd immunity, reducing the risk of outbreaks and protecting vulnerable populations who may not be able to get vaccinated. With better vaccine coverage, hospitalization rates could decrease, leading to substantial cost savings and freeing up resources for other critical needs. Given the evidence from prior studies and the identified gaps, our proposed project aims to leverage pharmacy intervention to enhance Pneumococcal vaccine acceptance rates during hospital admissions. This not only holds promise for better patient outcomes but also for broader public health and social welfare benefits.

HYPOTHESIS

Implementing Pneumococcal vaccine education intervention to patients during their inpatient hospital admission will increase their understanding of the importance of pneumonia immunization, thus resulting in increased vaccination acceptance rates prior to discharge compared to not receiving the education at all.

APPROXIMATE NUMBER OF SUBJECTS

Approximately 100 Geisinger patients will be approached for recruitment in the study, with 50 patients as controls and 50 patients as treatments. Recruitment will be defined when a patient meets eligibility criteria and is asked if they would like the vaccine prior to discharge, independent of any vaccine education intervention.

RECRUITMENT

All patients admitted to the inpatient Family Medicine service at Geisinger South Wilkes-Barre hospital will be screened for vaccine eligibility within the duration of their stay. Screening will take place by a medical resident using patient health information through electronic health records to determine eligibility based on inclusion/exclusion criteria for vaccine administration. Patients who pass the criteria threshold will be randomly placed in control and treatment groups accordingly to ensure a 1:1 ratio is acquired to ensure enough data points for data analysis. These patients will then be approached by a medical resident of the primary care team and inquire if they would like the vaccine with a yes or no decision. Patients who fall in the control group will only be presented with the vaccine option by the medical resident. In the treatment group, a pharmacy student will provide pneumonia vaccine education intervention to the patient before the resident asks if they would like the vaccine option. Ultimately after the vaccine decision from the patient, the resident will provide both control and treatment patients with a short questionnaire regarding their vaccination decision reasoning, regardless is the patient accepted or refused it or not.

APPROXIMATE DURATION OF PATIENT ENCOUNTER IN STUDY

Patients will be recruited for the study during the duration of their admission to Family Medicine services at Geisinger South Wilkes-Barre hospital. There will not be any follow-up, as all key events of recruitment and data collection occur prior to their discharge.

APPROXIMATE DURATION OF FULL STUDY

This study will be completed in approximately one year. The end of the study is the discharge of the final patient or the end of collection of data from the patient's electronic health record or questionnaire results.

PROCEDURES

Patients who qualify for the Prevnar 20 vaccine will be offered the opportunity for immunization prior to discharge during inpatient admission.

Screening for Eligibility:

All patients admitted to Family Medicine services at Geisinger South Wilkes-Barre hospital are eligible for the study. During the patient's stay, a Geisinger institutional review board-approved study team member will review the patient's electronic health record to determine if they meet the necessary inclusion and exclusion criteria requirements of the Prevnar 20 vaccine on a patient-by-patient basis. It is anticipated that approximately 2-3 patients could be screened per day.

Randomization:

If the patient meets the criteria and qualifies for Prevnar 20 immunization, they will be randomized into two groups (control or treatment) in a 1:1 ratio using a computer-generated sequence and allocation within the study's secure electronic database build. The randomization scheme will be developed by approved biostatistics personnel to ensure enough patients fall into each category for the study. The medical resident entering the patient into the database will note who which patients fall into each group to determine the next step in the study.

Patient Interaction:

Patients that are randomly selected as controls will be approached by the IRB-approved clinical resident offer the Prevnar 20 vaccination. If they accept, the patient will receive Prevnar 20 as a part of their standard care and immunized against the Pneumococcal virus. If they refuse, the patient will receive no vaccine as part of their standard care. In patients who randomly are placed in the treatment group, an assigned pharmacy student will first approach the patient and provide verbal education of important information on Prevnar 20, including benefits, risks, side effects, etc. Once education is completed, the clinician will approach the patient and ask if they would like the vaccine (like the control group). Vaccine acceptance/refusal will then be entered into the study's secure database as a data point for the study by the clinician.

Questionnaire:

In both control and treatment groups, the clinician will approach the patient and verbally present qualitative questions regarding their decision reasoning on why they accepted or refused the vaccine. This brief questionnaire will include different factors that may give insight in their decision making, and help determine correlations between different patient identifiers, presence or absence of education, and their final decision. Answers to these questions will be entered into the study's secure database when the patient encounter ends.

03

Conditions studied

  • Pneumonia, Pneumococcal
  • Vaccine

Keywords

  • Vaccine
  • Pneumococcal
  • Education
  • Interventional
  • Acceptance
  • Pneumonia
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients admitted to inpatient Family Medicine service with Type I and II Diabetes.
  • Patients who have not been previously vaccinated against pneumonia.
  • Patients meeting specific eligibility for Prevnar 20 vaccine: Over age of 65 OR have been diagnosed with any of the following: diabetes, , or asthma.

Exclusion criteria

Exclusion Criteria:

  • Patients that already received pneumonia vaccination in care history.
  • Patients with pneumonia inpatient diagnosis at time of recruitment.
  • Patients with any active infections.
  • Patients who are in an status.
  • Patients allergic to any components of the vaccine.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
141 participants (actual)

Study arms

  • No intervention
    Control

    Patients randomized into this arm DO NOT RECEIVE Pneumococcal vaccine education prior to given the option to accept or refuse the vaccine.

  • Experimental
    Treatment

    Patients randomized into this arm RECEIVE Pneumococcal vaccine education prior to given the option to accept or refuse the vaccine.

    Behavioral: Pneumococcal Vaccine Education

Interventions

  • BehavioralPneumococcal Vaccine Education

    Education provided to patients to inform them and increase their awareness on the benefits of getting vaccinated against Pneumococcal pneumonia

    Also known as: Educational

06

What researchers measure

Primary outcomes

  1. Number of patients accepting the Prevnar 20 Pneumococcal vaccine after receiving pharmacy-led education intervention during standard care.

    Patients answering "yes" when given the option to receive the Prevnar 20 Pneumococcal vaccine after they receive vaccine-specific education to increase their knowledge and awareness of the pneumonia vaccine.

    Time frame: Through study completion of up to one year.

07

Study locations

1 site
  • Geisinger South Wilkes-Barre
    Wilkes-Barre, Pennsylvania 18702, United States
08

References and documents

Publications

  • Robke JT, Woods M. A decade of experience with an inpatient pneumococcal vaccination program. Am J Health Syst Pharm. 2010 Jan 15;67(2):148-52. doi: 10.2146/ajhp080638. PubMed 20065270 ↗
  • Stinchfield PK. Practice-proven interventions to increase vaccination rates and broaden the immunization season. Am J Med. 2008 Jul;121(7 Suppl 2):S11-21. doi: 10.1016/j.amjmed.2008.05.003. PubMed 18589063 ↗
  • Coyle CM, Currie BP. Improving the rates of inpatient pneumococcal vaccination: impact of standing orders versus computerized reminders to physicians. Infect Control Hosp Epidemiol. 2004 Nov;25(11):904-7. doi: 10.1086/502317. PubMed 15566021 ↗
  • Rees S, Stevens L, Drayton J, Engledow N, Sanders J. Improving inpatient pneumococcal and influenza vaccination rates. J Nurs Care Qual. 2011 Oct-Dec;26(4):358-63. doi: 10.1097/NCQ.0b013e31821fb6bb. PubMed 21577146 ↗
  • McFadden K, Seale H. A review of hospital-based interventions to improve inpatient influenza vaccination uptake for high-risk adults. Vaccine. 2021 Jan 22;39(4):658-666. doi: 10.1016/j.vaccine.2020.12.042. Epub 2020 Dec 21. PubMed 33357955 ↗
  • Queeno BV. Evaluation of Inpatient Influenza and Pneumococcal Vaccination Acceptance Rates With Pharmacist Education. J Pharm Pract. 2017 Apr;30(2):202-208. doi: 10.1177/0897190016628963. Epub 2016 Jul 9. PubMed 26880320 ↗
  • Cotugno S, Morrow G, Cooper C, Cabie M, Cohn S. Impact of pharmacist intervention on influenza vaccine assessment and documentation in hospitalized psychiatric patients. Am J Health Syst Pharm. 2017 Dec 1;74(23 Supplement 4):S90-S94. doi: 10.2146/ajhp160755. PubMed 29167145 ↗
  • Ahmad Hamidi A, Gelmez Tas B, Gunduz A, Nur Celebi S, Esen ES, Toprak D, Dokmetas I. Immunization rates of pneumococcal, influenza and tetanus vaccines and knowledge and attitudes of adult patients who receive inpatient treatment at hospital: Point prevalence study. Hum Vaccin Immunother. 2018;14(11):2649-2653. doi: 10.1080/21645515.2018.1489187. Epub 2018 Jul 12. PubMed 29913102 ↗
  • Dodds ES, Drew RH, May DB, et al. Impact of a Pharmacy Student-Based Inpatient Pneumococcal Vaccination Program. AJPE 2001;65.

Individual participant data

Plan to share: No — There is no direct intent to share individual participant data related to this study. However, per institute policy, records of data generated during this study will be de-identified and will be kept for at least 6 years within the institutes secured database and then destroyed. Prior to destruction, the data will have the OPTION of being used for other Geisinger institutional review board-approved research if appropriate.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2024 to primary completion in Jan 2025, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2023
First posted
Nov 18, 2023
StartActual
May 6, 2024
Primary completionActual
Jan 26, 2025
CompletionActual
Jan 26, 2025
Last update
Jul 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06136832
Lead sponsor
Geisinger Clinic
Responsible party
Sponsor
First posted
Nov 18, 2023
Start date
May 6, 2024
Primary completion
Jan 26, 2025
Completion
Jan 26, 2025
Last update
Jul 8, 2025

Study contacts

Jason Woloski, MD
principal investigator · Geisinger Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion